Untitled

A Guide to VIREAD / Tenofovir Disoproxil Fumarate Online Purchases - Everything You Need to Know

https://www.thebody.com/health/hiv-viread-tenofovir-tdf

Viread (generic name: tenofovir disoproxil fumarate; often abbreviated as TDF) is an anti-HIV medication taken as one pill once a day in combination with other medications. Viread is in a class of drugs called “nucleoside / nucleotide reverse transcriptase inhibitors” (NRTIs), which stop HIV from making copies of itself.

Viread is available as a stand-alone drug, but it is usually used in combination with other drugs. Viread is included in a fixed-dose combination (FDC) pill called Truvada, which also includes an HIV drug called Emtriva (emtricitabine, FTC). Viread is also part of several other FDCs, including these single-dose treatment regimens (STRs) for HIV:

Atripla (TDF + FTC + Sustiva [efavirenz])

Complera (TDF + FTC + Edurant [rilpivirine])

Stribild (TDF + FTC + elvitegravir + cobicistat)

Viread was first approved by the U.S. Food and Drug Administration as a treatment for HIV in 2001. Generic versions of Viread are available in the U.S., and are included in a number of FDCs and STRs.

Viread is generally taken by adults as a single 300 mg pill orally once a day. Although the drug will work just as well whether it’s taken with or without food, taking Viread on an empty stomach can lead to abdominal pain or discomfort.

https://www.sfda.gov.sa/sites/default/files/2023-10/VireadBrochure.pdf

There are uncertainties associated with the long-term effects of bone and renal toxicity. Moreover, the reversibility of renal toxicity cannot be fully ascertained. Therefore, a multidisciplinary approach is recommended to adequately weigh on a case by case basis the benefit/risk balance of treatment, decide the appropriate monitoring during treatment (including decision for treatment withdrawal) and consider the need for supplementation.

In clinical studies and post-marketing safety surveillance of TDF in adults, events of renal failure, renal impairment, and proximal renal tubulopathy (including Fanconi syndrome) have been reported. In some patients proximal renal tubulopathy has been associated with myopathy, osteomalacia (manifested as bone pain and infrequently contributing to fractures), rhabdomyolysis, muscle weakness, hypokalaemia and hypophosphataemia.

This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider.

If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you are taking another drug that has the same drug in it. If you are taking adefovir. If you are taking any drugs that can raise the chance of kidney problems. There are many drugs that can do this. Ask your doctor or pharmacist if you are not sure. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug.

Tenofovir, sold under the brand name Viread, is a once-daily treatment for HIV infection. Tenofovir is also co-formulated with other medicines:

• Truvada: tenofovir + FTC

• Atripla: tenofovir + FTC + efavirenz

 • Complera: tenofovir + FTC + rilpivirine

• Stribild: tenofovir + FTC + cobicistat + elvitegravir

When HIV infects a cell, it takes control of that cell. HIV then forces the cell to make many more copies of the virus. To make these copies, the cell uses proteins called enzymes. When the activity of these enzymes is reduced the production of HIV slows.

https://www.tga.gov.au/sites/default/files/auspar-tenofovir-disoproxil-fumarate-131014-pi.pdf

Tenofovir disoproxil fumarate is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in water at 25°C. The partition coefficient (log P) for tenofovir disoproxil is 1.25 and the pKa is 3.75. The active pharmaceutical product is a single enantiomer that does not undergo racemisation either in vitro or in vivo.

VIREAD tablets contain the following ingredients as excipients: Core: microcrystalline cellulose (E460), pregelatinised maize starch, croscarmellose sodium, lactose and magnesium stearate (E572). Coating: Opadry II Y-30-10671-A-(ARTG3968).

Each VIREAD tablet is light blue and almond-shaped. Each tablet is debossed on one side with the markings “GILEAD” and “4331” and on the other side with the marking “300”. The tablets are supplied in bottles with screw cap closures.